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Abstract
Background
We investigated whether adherence to breast screening would yield a clinical benefit even
among patients with small breast cancer (2 cm) by comparing differences between those
who did and did not adhere to breast screening.
Methods
Patients who were diagnosed with invasive T1 breast cancer and treated at Gangnam Sev-
erance Hospital from January 2006 to June 2014 were included. Of the 632 study patients,
450 and 182 were classified as screen-adherent and non-adherent. Adherence to the breast
screening program was defined as the completion of breast screening examinations within 3
years before cancer diagnosis. Recurrence-free survival (RFS) and metastasis-free survival
(MFS) were compared between the groups. Propensity score matching were applied to
compare survival outcome.
Results
Adherent patients were more likely to have a lower histologic grade (P < 0.001), high estro-
gen receptor expression (P = 0.040), and lower HER2-positivity (P = 0.026). The adherent
group had more favorable subtypes compared to the non-adherent group, with a greater
percentage of Luminal/HER2-negative subtype (66.7% vs. 56.5%) and a lower percentage
of HER2 subtype (8.3% vs. 16.7%). The RFS and MFS were significantly better in the adher-
ent group (P = 0.003, 0.010, respectively). In the case-matched cohort, superior survival of
the adherent group was maintained.
Conclusions
Adherence to breast screening in patients with small breast tumors was associated with
more favorable tumor biology and better prognosis. Our findings suggest that adherence to
PLOS ONE | https://doi.org/10.1371/journal.pone.0186988 November 2, 2017 1 / 10
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Park JM, Bae SJ, Yoon C, Lee HS, Lee
HW, Ahn SG, et al. (2017) Comparison of patients
with small (2 cm) breast cancer according to
adherence to breast screening program. PLoS ONE
12(11): e0186988. https://doi.org/10.1371/journal.
pone.0186988
Editor: William B. Coleman, University of North
Carolina at Chapel Hill School of Medicine, UNITED
STATES
Received: July 3, 2017
Accepted: October 11, 2017
Published: November 2, 2017
Copyright: © 2017 Park et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This research was supported by the Basic
Science Research Program through the NRF,
funded by the Ministry of Science, ICT, & Future
Planning (NRF-2015R1C1A1A02037104), and
grant from the National R&D Program for Cancer
Control, Ministry of Health & Welfare, Republic of
Korea (1520120). The funders had no role in study
breast screening might offer clinical benefits in terms of tumor biology as well as early
detection.
Introduction
The goal of cancer screening is early tumor detection, followed by appropriate treatment. Reg-
ular screening mammography for breast cancer has been widely recommended and is sup-
ported by solid evidence: most population-based randomized controlled trials have reported
reduced mortality among women who undergo screening mammography [1–5]. As in other
developed countries, a national health screening program in the Republic of Korea initiated a
population-based mammography screening program in 1999 [6].
Breast tumors detected by mammography screening are known to be smaller than those
detected outside of screening [7–11]; accordingly, better prognosis is largely observed in popu-
lations wherein cancer is detected through screening programs. Of note, studies have also
shown that mammographic cancer detection is associated with a better prognosis than that of
similarly sized tumors found outside of screening [7–9,11–17]. These studies suggest that
breast screening itself could be considered a favorable prognostic variable independent of the
primary tumor size, axillary metastasis, age at cancer diagnosis, and tumor grade. Additionally,
even among patients with ductal carcinoma in situ (DCIS), those with screening-detected
tumors had better outcomes than did those with symptom-detected tumors [18].
In this study, we investigated whether adherence to a breast screening program would yield
clinical benefit even among patients with small invasive breast cancers, as outcomes might be
less affected by the detection method. We compared the pathological and biological differ-
ences, including the proportions of immunohistochemistry (IHC)-based subtypes, between
groups of patients who did and did not adhere to a screening program.
Materials and methods
Study population
The institutional review board of Gangnam Severance Hospital, Yonsei University, Seoul,
Korea, approved this study, which was conducted in accordance with good clinical practice
guidelines and the Declaration of Helsinki. The need for informed consent was waived because
of the retrospective design, under the approval of the institutional review board. Patients with
T1 breast cancer who were treated at Gangnam Severance Hospital between January 2006 and
June 2014 were identified. We excluded patients with bilateral breast cancer and those who
were treated with neoadjuvant chemotherapy. Women younger than age 40 years were also
excluded because general population screening was recommended from age 40 years. Raw
data of these patients is provided online (S1 Data).
Tumor detection method
Physicians in the Breast Cancer Center of Gangnam Severance Hospital interviewed patients
and documented information about the tumor detection method in the medical charts. Adher-
ence to the breast screening program was defined as the completion of breast screening exami-
nations within 3 years prior to the diagnosis of breast cancer because the Korean national
health screening program offers biennial mammography screening. The completion of private
mammography was also considered adherence to the breast screening program. Patients who
Adherence to breast screening
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had never participated in a breast screening program or completed screening3 years before
a diagnosis of breast cancer were classified as non-adherent. The patients for whom informa-
tion about the breast screening program was not available were considered unclassified.
With a consideration of mammographic density which affects results of screening program,
we included mammographic density category evaluated by Breast Imaging Reporting and
Data System (BI-RADS).
Immunohistochemistry markers
For our IHC study, we stained formalin-fixed, paraffin-embedded tissue sections obtained
from surgical specimens using appropriate antibodies specific for four markers: estrogen
receptor (ER; 1:100 dilution, clone 6F11; Novocastra, Newcastle upon Tyne, UK), progester-
one receptor (PR; clone 16; Novocastra, UK), human epidermal growth factor receptor 2
(HER2; 4B5 rabbit monoclonal antibody; Ventana Medical Systems, Tucson, AZ, USA), and
Ki-67 (MIB-1; Dako, Glostrup, Denmark). Patients were stratified by ER and PR IHC test
results into four groups using the modified Allred system: strong, Allred score 7–8; moderate,
Allred score 5–6; weak, Allred score 2–4; and negative, Allred score 0–1 [19]. The HER2 status
was defined as positive with a score of 3+ and negative with a score of 0 or 1+ [20]. Tumors
with scores of 2+ were sent for fluorescent in situ hybridization (FISH) analysis, according to
the protocol given by the supplier (PathVysion kit; Vysis, Downers Grove, IL, USA or HER2
inform; Ventana). Ki67 expression was measured by an experienced pathologist and reported
as a percentage of positive tumor cells (range: 0–100%).
IHC-based subtype
Tumors were classified into four molecular subtypes based on ER, PR, HER2 expression: lumi-
nal-HER2 negative (ER+ and/or PR+, HER2-), luminal-HER2-positive (ER+ and/or PR+,
HER2+), HER2 (ER-, PR-, HER2+), and triple-negative breast cancer (TNBC; ER-, PR-,
HER2-).
Statistical analysis
Continuous variables such as age and tumor size were compared by Mann–Whitney U test.
Discrete variables were compared using the chi-square test. Recurrence-free survival (RFS)
was measured from the date of the first curative surgery to the date of the first loco-regional
recurrence or distant metastasis. Metastasis-free survival (MFS) was measured from the date
of the first curative surgery to the date of the first distant metastasis. The Kaplan–Meier
method was used to estimate the RFS and MFS, and the estimated survival curves were com-
pared using the log-rank test. Using Harrell c-statistic, the concordance index (c-index) was
calculated to measure the concordance for time-to event data, in which increasing values
between 0.5 and 1.0 indicated improved prediction. The Cox’s regression-hazard model was
used for univariate and multivariable survival analyses.
To adjust for potential confounding factors, we performed an individual propensity score-
matching method using a Greedy algorithm in which randomly selected individuals in the
adherent group were paired with comparable individuals in the non-adherent group. The one
control per one case was selected based on tumor size, lymph node metastasis, histologic
grade, ER, and HER2.
All analyses were performed using SPSS version 18 (SPSS; Chicago, IL, USA) and SAS (ver-
sion 9.4, SAS Inc., Cary, NC, USA). Statistical significance was defined as a P-value < 0.05 or a
95% confidence interval (CI) that did not include 1.
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Results
Comparisons of clinical and pathologic characteristics
A total of 684 patients were included; of these, 450, 182, and 52 were categorized as screen-
adherent, non-adherent, and unclassified, respectively. We further compared the clinical and
pathological characteristics between the adherent and non-adherent groups (Table 1). Patients
who adhered to the breast screening were more likely to have smaller tumors (P< 0.001) than
were the non-adherent patients. Although 490 patients (77.5%) had node-negative disease, the
non-adherent group was more likely to have a higher nodal stage (P = 0.004). The non-adher-
ent patients had more advanced stage disease (P< 0.001), higher histologic grade (P< 0.001),
higher ER-negative rate (P = 0.040), and higher HER2 positive rate (P = 0.026). Regarding
adjuvant treatments, the adherent group was more likely to receive breast-conserving surgery
(P< 0.001) and endocrine therapy (P = 0.007), and less likely to receive chemotherapy
(P< 0.001).
Moreover, we described our two groups in relation to the presence of symptoms (S1 Fig).
All of the non-adherent had positive symptoms, while 161 (35.8%) of the adherent had positive
symptoms. Details of symptoms in relation to the screening-adherence were presented in S1
Table.
Comparisons for IHC-based subtypes
In intergroup comparisons of IHC-based subtype frequencies, the adherent group had more
favorable subtypes compared to the non-adherent group, with a greater percentage of Lumi-
nal/HER2-negative subtype (66.7% vs. 56.5%) and a lower percentage of HER2 subtype (8.3%
vs. 16.7%; Fig 1).
Clinical outcomes
During a median follow-up period of 59 (range: 12–131) months, there were 22 recurrences
occurred, including 5 loco-regional and 17 distant metastases. The RFS and MFS differed sig-
nificantly according to adherence to the breast screening program based on the log-rank test
(P = 0.003 and P = 0.010, respectively; Fig 2).
To demonstrate the adherence to screening as an independent prognostic factor, we con-
ducted our analyses in two ways. First, multivariate models for RFS and MFS were constructed
using the Harrell c-statistic. In a multivariate analysis using a Cox regression hazard model,
adherence to breast screening (adjusted hazard ratio: 2.974; 95% CI: 1.280–6.909) was identi-
fied as a prognostic factor for RFS, independent of the nodal status, tumor size, nodal status,
grade, ER status (Table 2). In a multivariate model for MFS, the adherence showed a marked
trend toward a significant prognostic factor (adjusted hazard ratio: 2.464; 95% CI: 0.876–
6.932).
In addition, to adjust for potential confounding factors including adjuvant treatments, we
adopted case-matching method, and assigned 137 patients for each group. Of the 274 patients
in the propensity-matched cohorts, tumor characteristics and adjuvant treatments were not
different according to the adherence to screening (Table 1). In the matched cohort, 12 women
showed recurrences, with 2 loco-regional and 10 distant recurrences. Improved RFS and MFS
of the adherent group was still observed (P = 0.009 for RFS, P = 0.024 for MFS; Fig 3).
Discussions
Even in this modern era characterized by advances in systemic therapy, screening mammogra-
phy for the detection of early-stage breast cancers remains associated with a reduction in breast
Adherence to breast screening
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Table 1. Clinical and pathologic characteristics according to the screen-adherence.
Original Cohort Case-matched cohort
Variables Screening-adherence
(n = 450)
Screening-non-
adherence (n = 182)
P-value Screening-adherence
(n = 137)
Screening-non-
adherence (n = 137)
P-
value
Age, median (range) 51 (40–87) 49 (40–82) 0.055 50 (40–84) 49 (40–82) 0.462
Tumor size, median
(range)
1.2 (0.1–2.0) 1.5 (0.3–2.0) <0.001 1.5 (0.3–2.0) 1.5 (0.3–2.0) 0.872
Mammographic
density a, b
0.094 0.348
I 11 (2.7) 2 (1.2) 4 (3.1) 1 (0.8)
II 51 (12.4) 32 (18.6) 16 (12.5) 22 (17.1)
III 286 (69.8) 120 (69.8) 91 (71.1) 93 (72.1)
IV 62 (15.1) 18 (10.5) 17 (13.3) 13 (10.1)
T stage <0.001 0.878
T1a 47 (10.4) 6 (3.3) 6 (4.4) 6 (4.4)
T1b 115 (25.6) 24 (13.2) 19 (13.9) 22 (16.1)
T1c 288 (64.0) 152 (83.5) 112 (81.8) 109 (79.6)
N stage 0.004 0.802
0 356 (79.1) 133 (73.1) 103 (75.2) 106 (77.4)
N1 89 (19.8) 38 (20.9) 32 (23.4) 30 (21.9)
N2 4 (0.9) 8 (4.4) 2 (1.5) 1 (0.7)
N3 1 (0.2) 3 (1.6)
Stage <0.001 0.988
I 366 (81.3) 136 (74.7) 109(79.6) 108 (78.8)
II 80 (17.8) 35 (19.2) 26 (19.0) 27 (19.7)
III 4 (0.9) 11 (6.0) 2 (1.5) 2 (1.5)
Grade a <0.001 0.881
I or II 373 (86.9) 126 (72.0) 110 (80.3) 108 (78.8)
III 56 (13.1) 49 (28.0) 27 (19.7) 29 (21.2)
Estrogen receptor c 0.040 0.398
Positive 334 (74.2) 120 (65.9) 95 (69.3) 92 (67.2)
Negative 116 (25.8) 62 (34.1) 42 (30.7) 45 (32.8)
Progesterone receptor
c
0.471 0.623
Positive 280 (62.2) 107 (58.8) 84 (61.3) 79 (57.7)
Negative 170 (37.8) 75 (41.2) 53 (42.3) 58 (42.3)
HER2 0.026 0.352
Negative 351 (81.2) 122 (72.6) 115 (83.9) 108 (78.8)
Positive 81 (18.8) 46 (27.4) 22 (16.1) 29 (21.2)
Ki67 a 0.194 1.000
20 87 (19.4) 44 (24.2) 32 (23.4) 32 (23.4)
<20 362 (80.6) 138 (75.8) 105 (76.6) 105 (76.6)
Surgery <0.001 0.182
BCS 287 (63.8) 87 (47.8) 81 (59.1) 69 (50.4)
TM 163 (36.2) 95 (52.2) 56 (40.9) 68 (49.6)
Chemotherapy <0.001 0.146
Not given 248 (55.1) 70 (38.7) 70 (51.1) 57 (41.6)
Given 202 (44.9) 111 (61.3) 67 (48.9) 80 (58.4)
Endocrine therapy 0.007 0.256
Not given 83 (18.4) 52 (28.6) 28 (20.4) 37 (27.0)
(Continued )
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cancer-related mortality [5,21]. In our selected group of patients with small tumors, who were
selected to circumvent the effects of early detection via screening programs, the positive effect
of breast screening was substantiated in terms of tumor biology and clinical outcome. We
found that when compared with tumors diagnosed outside of a breast screening program,
those detected via screening had more favorable biologic characteristics and, consequently, a
better prognosis, despite the small tumor size (2 cm).
Previous studies have shown a link between screening-detected tumors and a less aggressive
biological profile, including a lower histologic grade and mitotic count, strong ER and PR
expression, reduced HER2 expression, and a lower cell proliferation rate, compared with
symptom-detected tumors. In support of these findings, another study used a novel tumor
genotyping approach to demonstrate that symptom-detected tumors have higher copy number
gains, compared with screen-detected tumors [22]. Likewise, our findings regarding the better
Table 1. (Continued)
Original Cohort Case-matched cohort
Variables Screening-adherence
(n = 450)
Screening-non-
adherence (n = 182)
P-value Screening-adherence
(n = 137)
Screening-non-
adherence (n = 137)
P-
value
Given 367 (81.6) 130 (71.4) 109 (79.6) 100 (73.0)
Radiotherapy 0.040 0.394
Not given 170 (37.8) 85 (46.7) 56 (40.9) 64 (46.7)
Given 280 (62.2) 97 (53.3) 81 (59.1) 73 (53.3)
a Missing value
b Mammographic density was categorized according to Breast Imaging Reporting and Data System
c Positive, Allred score 2–8; Negative, Allred score 0–1.
Abbreviations: HER2, human epidermal growth factor receptor 2; BCS, breast-conserving surgery; TM, total mastectomy
https://doi.org/10.1371/journal.pone.0186988.t001
Fig 1. Comparisons of immunohistochemistry (IHC)-based subtypes between groups that did or did not adhere to breast screening.
Screening-adherent patients more frequently presented with a favorable subtype (66.7% vs. 56.5% for Luminal/HER2-negative), and less frequently
presented with an aggressive subtype, compared with non-adherent patients (8.3% vs. 16.7% for HER2).
https://doi.org/10.1371/journal.pone.0186988.g001
Adherence to breast screening
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biologic characteristics of tumors diagnosed via breast screening were concordant with find-
ings from previous studies.
A previous study of DCIS compared the subtype frequencies among screen-detected
tumors and symptom-detected tumors [18]. In that study, favorable subtypes were more fre-
quent among screen-detected DCIS cases, compared with symptom-detected cases. In
Fig 2. Kaplan–Meier plots of recurrence-free survival (RFS) and metastasis-free survival (MFS) according to adherence to breast screening.
(A) The RFS and (B) MFS differed significantly according to the adherence status (P = 0.003 and P = 0.010, respectively, log-rank test).
https://doi.org/10.1371/journal.pone.0186988.g002
Table 2. Multivariate survival analyses of recurrence-free survival and metastasis-free survival.
Variables Recurrence-free survival Metastasis-free survival
Multivariate (P) Hazard ratio (95% CI) Multivariate (P) Hazard ratio (95% CI)
T stage 0.762 0.796
T1a /b Reference Reference
T1c 1.195 (0.379–3.766) 0.853 (0.255–2.849)
N stage 0.717 0.260
Negative Reference Reference
Positive 1.196 (0.452–3.164) 1.814 (0.644–5.106)
ER 0.442 0.277
Positive Reference Reference
Negative 1.569 (0.497–4.949) 2.814 (0.534–8.933)
Histologic grade 0.460 0.763
I and II Reference Reference
III 1.1.536 (0.492–4.793) 1.239 (0.308–4.977)
Adherence 0.033 0.087
Adherence Reference Reference
Non-Adherence 2.974 (1.280–6.909) 2.464 (0.876–6.932)
Multivariate P values: Cox regression hazard model
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2
https://doi.org/10.1371/journal.pone.0186988.t002
Adherence to breast screening
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accordance with this study, we found that the adherent group had a higher rate of luminal/
HER2-negative and a lower rate of TNBC, compared with the non-adherent group.
A lower rate of chemotherapy given could be addressed as another advantage of the adher-
ence to breast screening (45.4% in the adherence vs.62.3% in the non-adherence). In our
study, the patients with adherence to breast screening showed a better outcome than the
patients with non-adherence despite of a lower rate of adjuvant chemotherapy. It is reasonable
because the non-adherence group had higher rates of HER2 expression and TNBC subtype.
The higher chance of sparing toxicity from chemotherapy in the adherence group would be
recognized as the benefit of breast screening program.
We recognize that our study had some limitations. One major caveat is the retrospective
design, as well as the inclusion of a small number of patients from a single institute. Future
studies involving multi-institutional databases are warranted to affirm our results. Also,
another limitation is to acknowledge that clinical outcome can be affected by various variables
including duration of endocrine treatments and complexity of clinical behavior, which are not
fully considered in our analyses. Thus, our findings should be carefully integrated into current
knowledge on pro and cons of breast screening program. Despite these limitations, one
strength of our study is the population included in the study, which represents patients treated
in daily practice because the definition of breast screening included private practice breast
screening, as well as the national screening program. Furthermore, our findings obtained
among selected patients with small, early-phase tumors further support the use of breast
screening, as tumors detected using this modality remained associated with better tumor bio-
logic characteristics and a favorable prognosis.
Conclusions
Breast cancers identified under adherence to breast screening are associated with a more favor-
able tumor biology and better prognosis, even during the early phase. Our findings suggest
Fig 3. Kaplan–Meier plots of recurrence-free survival (RFS) and metastasis-free survival (MFS) according to adherence to breast screening
in the case-matched cohort. (A) The RFS and (B) MFS differed significantly according to the adherence status (P = 0.009 and P = 0.024,
respectively, log-rank test).
https://doi.org/10.1371/journal.pone.0186988.g003
Adherence to breast screening
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that adherence to breast screening, in addition to providing early detection, may yield clinical
benefits due to more favorable tumor biology and outcomes.
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